CD19+CD22 CAR T-cells

CD19+CD22 CAR T-cells is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by University College London (UCL) and its spin-off Autolus Therapeutics. The therapy utilizes a dual-targeting approach, where patient-derived T cells are engineered via lentiviral transduction to express two distinct CARs: a 'fast-off' rate anti-CD19 CAR (derived from AUTO1/obecabtagene autoleucel) and a novel anti-CD22 CAR designed for high sensitivity to low antigen density. By simultaneously targeting both CD19 and CD22 antigens on leukemic B cells, the therapy aims to mitigate the risk of relapse caused by antigen-loss escape, a common failure mechanism in single-target CAR-T therapies. It is primarily being evaluated in Phase I clinical trials (such as the CARPALL study, NCT02443831) for the treatment of pediatric and young adult patients with high-risk or relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).

Other names

CD19/CD22 dual-targeted CAR T-cellsCD19/CD22 CAR-T